Evidence mapPaperPMID 42548820Full record

ArticleFrontiers in medicine2026

Integrating fine needle aspiration and single-cell RNA sequencing for studying metabolic dysfunction-associated steatotic liver disease.

Matthew P Salomon, Lucy Golden-Mason, Ivetta Vorobyova, Gary C Kanel, Yufen Wang, Daphne Wong, Ana C Maretti-Mira

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew P Salomon *Department of Cancer Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Lucy Golden-Mason *Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Ivetta VorobyovaMolecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Gary C KanelDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Yufen WangDivision of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Daphne WongDepartment of Cancer Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Ana C Maretti-MiraDivision of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the leading cause of chronic liver disease and hepatocellular carcinoma. The immune response plays a central role in disease onset and progression and is the focus of many experimental studies. However, traditional models typically rely on terminal sampling procedures that require large tissue quantities, a substantial number of animals per experimental condition, and cross-sectional study designs. Methods: Here, we propose integrating two powerful techniques to longitudinally study a MASLD animal model: image-guided fine-needle aspiration (FNA) and single-cell RNA sequencing (scRNA-seq). Results: This framework enables safe, high-precision longitudinal sampling of a limited number of animals, allowing simultaneous profiling of innate and adaptive immune cells during metabolic dysfunction-associated steatohepatitis (MASH) progression induced by a high-fat, high-cholesterol, and high-fructose diet. We further identified dynamic shifts in the hepatic immune landscape following dietary intervention. Conclusion: Our findings support the feasibility of the FNA-scRNA-seq framework as a novel tool for longitudinal immune profiling in preclinical MASLD and MASH studies and highlight its potential to reduce animal use in chronic liver disease research.

Indexed as

immunologyMASHMASLDmolecular biologynew approach methodology

Identifiers

PMID42548820
PMCPMC13429742

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.